Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials - Brown, Jennifer R.; Moslehi, Javid; O’Brien, Susan; Ghia, Paolo; Hillmen, Peter; Cymbalista, Florence; Shanafelt, Tait D.; Fraser, Graeme; Rule, Simon; Kipps, Thomas J.; Coutre, Steven; Dilhuydy, Marie-Sarah; et al. (Haematologica (Roma), 2017)
Keywords: Adult; Aged; Aged, 80 and over; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Atrial Fibrillation - diagnosis; Atrial Fibrillation - epidemiology; Atrial Fibrillation - etiology; Atrial Fibrillation - therapy; Disease Management; Female; Follow-Up Studies; Hemorrhage - etiology; Humans; Incidence; Life Sciences; Male; Middle Aged; Protein Kinase Inhibitors - adverse effects; Protein Kinase Inhibitors - therapeutic use; Pyrazoles - adverse effects; Pyrazoles - therapeutic use; Pyrimidines - adverse effects; Pyrimidines - therapeutic use; Randomized Controlled Trials as Topic; Risk Factors; Time Factors